Lung metastases treated with stereotactic body radiotherapy: the RSSearch patient Registry's experience. (Record no. 2623)

MARC details
000 -LEADER
fixed length control field 04713nam a22004937a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170830s20172017 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1748-717X
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 28143558
245 ## - TITLE STATEMENT
Title Lung metastases treated with stereotactic body radiotherapy: the RSSearch patient Registry's experience.
251 ## - Source
Source Radiation Oncology. 12(1):35, 2017 Feb 01
252 ## - Abbreviated Source
Abbreviated source Radiat. oncol.. 12(1):35, 2017 Feb 01
253 ## - Journal Name
Journal name Radiation oncology (London, England)
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2017
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2017
266 ## - Date added to catalog
Date added to catalog 2017-08-30
520 ## - SUMMARY, ETC.
Abstract CONCLUSION: Excellent OS and LC is achievable with SBRT utilizing BED >=100Gy<sub>10</sub> for lung metastases according to the RSSearch Registry data. Patients with small lung metastases (volumes<11 cc) had better LC and OS when using SBRT doses of BED >=100Gy<sub>10</sub>. Further studies to evaluate a difference, if any, between various tumor types will require a larger number of patients.
520 ## - SUMMARY, ETC.
Abstract METHODS: Seven hundred two patients were identified with lung metastases in the RSSearch Registry. Of these patients, 577 patients had SBRT dose and fractionation information available. Patients were excluded if they received prior surgery, radiation, or radiofrequency ablation to the SBRT treated area. Between April 2004-July 2015, 447 patients treated with SBRT at 30 academic and community-based centers were evaluable for overall survival (OS). Three hundred four patients with 327 lesions were evaluable for local control (LC). All doses were converted to Monte Carlo equivalents and subsequent BED Gy<sub>10</sub> for dose response analysis.
520 ## - SUMMARY, ETC.
Abstract OBJECTIVES: To report overall survival and local control for patients identified in the RSSearch Patient Registry with metastatic cancer to the lung treated with SBRT.
520 ## - SUMMARY, ETC.
Abstract RESULTS: Median age was 69 years (range, 18-93 years). Median Karnofsky performance status (KPS) was 90 (range 25/75% 80-100). 49.2% of patients had prior systemic therapy. Median metastasis volume was 10.58 cc (range 25/75% 3.7-25.54 cc). Site of primary tumor included colorectal (25.7%), lung (16.6%), head and neck (11.4%), breast (9.2%), kidney (8.1%), skin (6.5%) and other (22.1%). Median dose was 50 Gy (range 25/75% 48-54) delivered in 3 fractions (range 25/75% 3-5) with a median BED of 100Gy<sub>10</sub> (range 25/75% 81-136). Median OS for the entire group was 26 months, with actuarial 1-, 3-, and 5-year OS of 74.1%, 33.3, and 21.8%, respectively. Patients with head and neck and breast cancers had longer median OS of 37 and 32 months respectively, compared to colorectal (30 months) and lung (26 months) which corresponded to 3-year actuarial OS of 51.8 and 47.9% for head and neck and breast respectively, compared to 35.8% for colorectal and 31.2% for lung. The median LC for all patients was 53 months, with actuarial 1-, 3-, and 5-year LC rates of 80.4, 58.9, and 46.3%, respectively. There was no difference in LC by primary histologic type (p=0.49). Improved LC was observed for lung metastases that received SBRT doses of BED >=100Gy<sub>10</sub> with 3-year LC rate of 77.1% compared to 45% for lung metastases treated with BED<100Gy<sub>10</sub> (p=0.01). Smaller tumor volumes (<11 cc) had improved LC compared to tumor volumes>11 cc. (p=0.005) Two-year LC rates for tumor volumes<11 cc, 11-27 cc and>27 cc were 72.9, 64.2 and 45.6%, respectively. This correlated with improved OS with 2-year OS rates of 62.4, 60.9 and 46.2% for tumor volumes<11 cc, 11-27 cc and>27 cc, respectively (p=0.0023). In a subset of patients who received BED >=100Gy<sub>10</sub>, 2-year LC rates for tumor volumes<11 cc, 11-27 cc and>27 cc were 82.8, 58.9 and 68.6%, respectively (p=0.0244), and 2-year OS rates were 66.0, 58.8 and 28.5%, respectively (p=0.0081).
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Lung Neoplasms/sc [Secondary]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Lung Neoplasms/su [Surgery]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Radiosurgery
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Registries/sn [Statistics & Numerical Data]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adolescent
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged, 80 and over
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prognosis
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Radiotherapy Dosage
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Survival Rate
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Young Adult
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Franklin Square Medical Center
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Perry, David
790 ## - Authors
All authors Creach KM, D'Ambrosio D, Davis J, Kolker J, Lanciano R, Pablo J, Perry D, Rate W, Ricco A, Sharma S, Sundararaman S, Yang J
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1186/s13014-017-0773-4">https://dx.doi.org/10.1186/s13014-017-0773-4</a>
Public note https://dx.doi.org/10.1186/s13014-017-0773-4
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 08/30/2017   28143558 28143558 08/30/2017 08/30/2017 Journal Article

Powered by Koha